Literature DB >> 12524651

18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer.

Deshan S Zhao1, Ana Y Valdivia, Yi Li, M Donald Blaufox.   

Abstract

Positron emission tomography (PET) imaging is not used routinely in small-cell lung cancer (SCLC) but has been proven useful in non-small-cell lung cancer. The performance of (18)F-fluorodeoxyglucose (FDG)-PET in patients with SCLC was evaluated in this study. Fifteen patients with proven SCLC were evaluated (8 men and 7 women; mean age, 68 years; range, 50-81 years). Among the 15 patients with SCLC, 3 were newly diagnosed and 12 had received chemotherapy or radiation therapy before PET. Five patients underwent surgery (3 newly diagnosed and 2 after therapy) after PET scan, and 14 received chemotherapy, radiation therapy, or both. The patient who was not treated with chemotherapy or radiation therapy underwent surgery only. All patients had computed tomographic (CT) scans before PET and had clinical follow-up for at least 2 months after PET. The patients received 3.4 to 4.15 mCi of (18)F-FDG intravenously after fasting for at least 4 hours. Whole-body PET scans were acquired approximately 50 min after injection by using an ADAC Laboratories C-PET plus scanner. Among the 12 patients treated before PET, 2 were found with solitary pulmonary nodules positive on PET. Subsequent surgical resection and pathology showed 1 true positive and 1 false positive (postradiation pneumonitis). Six of these 12 patients had extrapulmonary metastases or large intense hilar or pulmonary uptake on PET, or both. Four of these 12 had no evidence of abnormal FDG uptake and were considered true negatives. The 3 patients with newly diagnosed SCLC were all true positives on PET, confirmed by surgery. One false negative on CT scan was attributed to postradiation fibrosis. These preliminary data suggest that whole-body FDG-PET can provide the basis for determining which treatment modality would be the most appropriate during the early stages of SCLC, when surgery is still an option, and it is a useful tool to assess the effect of treatment in patients with this disease. A more accurate assessment of SCLC will be possible if FDG-PET scan is combined with CT during the early evaluation of these patients. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12524651     DOI: 10.1053/snuc.2002.126052

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  6 in total

1.  Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer.

Authors:  Adedayo A Onitilo; Jessica M Engel; Jennifer M Demos; Bickol Mukesh
Journal:  Clin Med Res       Date:  2008-09-18

2.  Positron emission tomography: a false negative result in cystic encephalic mestastases from a small cell bronchial carcinoma.

Authors:  David Orts Giménez; Rosa Jiménez Yáñez; Antonia Galán Dávila; Gaspar Esquerdo Galiana; Eleuterio Llorca Martínez; Ana Belso Candela; Javier Mallada; Cristina Llorca Ferrándiz; José Manuel Cervera
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

3.  [Extra-pulmonary small-cell cancer: is its outcome similar to small cell lung cancer?].

Authors:  Angel Guerrero Zotano; Angel Segura Huerta; Lorena Pellín Ariño; Laura Palomar Abad; Jorge Molina Saera; José Ponce Lorenzo; Joaquín Montalar Salcedo
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

4.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.

Authors:  I Brink; T Schumacher; M Mix; S Ruhland; E Stoelben; W Digel; M Henke; N Ghanem; E Moser; E U Nitzsche
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-17       Impact factor: 9.236

5.  Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Authors:  Thierry Jacob; Dany Grahek; Nassima Younsi; Khaldoun Kerrou; Nicolas Aide; Françoise Montravers; Sonia Balogova; Cecile Colombet; Virginie De Beco; Jean N Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-10       Impact factor: 9.236

6.  Early assessment of therapeutic response using FDG PET in small cell lung cancer.

Authors:  Y Yamamoto; R Kameyama; M Murota; S Bandoh; T Ishii; Y Nishiyama
Journal:  Mol Imaging Biol       Date:  2009-05-12       Impact factor: 3.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.